Home CONTACT Neoplasma 2008 Neoplasma Vol.55, No.3, p.239-245, 2008

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.55, No.3, p.239-245, 2008

Title: The use of high dose rate endobronchial brachytherapy to palliate symptomatic recurrence of previously irriadiated lung cancer

Abstract: Endobronchial obstruction associated with lung cancer represents a common and potentially life threatening complication of newly diagnosed or recurrent disease. The vast majority of patients with obstructive lesions are not curable so it is desirable to palliate these patients as quickly as possible without compromising quality of life. High dose rate brachytherapy (HDR-BT) represents a therapeutic option with several advantages over external beam radiotherapy (EBRT), particulary in previous irradiated patients. The primary objective of this retrospective analysis was to assess palliation efficacy and complication rate of repeated brachytherapy treatment in previously irradiated patients. Between July 2000 and December 2005, 270 patients with endobronchial recurrence after prior given HDR-BT and / or another treatment modality were again treated with HDR-BT. It makes 270 of 1036 patients (26 %) treated on lung cancer with HDR-BT at all in this period. Brachytherapy was delivered with a dose per fraction 8 or 10 Gy specified from the center of the source at 0,5 or 1,0 cm. The symptomatic response rate were as follows: dyspnea had a 76 % response rate, cough 77 % response rate, hemoptysis 92 % response rate, and postobstructive pneumonia 82 % response rate, respectively. Among 270 of the patients 218 had follow up endoscopic examination (1 – 3 months after brachytherapy completion). Total response rate in this group was 80 %. Of 200 patients whose chest x-ray showed evidence of collapse or atelectasis caused by endobronchial recurrence obstruction, 146 (73 %) had evidence of reaeration. The median duration of palliation, marked by symptoms or a chest x-ray that worsened was five months, the range varing from 2 to 14 months. We have noticed superficial mucosal necrosis in 166 of patients (61,5 %) and broncho – osephagal fistula in 6 of patients (2,2 %). Repeated HDR-BT effectively relieves the symptoms of endobronchial obstruction due to recurrent lung cancer and can be given safely as an outpatient procedure. Future studies should aim to determine the maximum tolerated dose and appropriate patient selection.

Keywords: repeated HDR brachytherapy, reirradiation, endobronchial recurrence, palliation
Year: 2008, Volume: 55, Issue: 3 Page From: 239, Page To: 245

Price: 16.80 €

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.